National Cancer Institute
U.S. National Institutes of Health |

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
About NCI
    Cancer Studies Highlighted in the NCI Cancer Bulletin  
    Posted: 12/18/2007
Page Options
Print This Page
E-Mail This Document
Search by Cancer Type
Breast Cancer

Colon and Rectal Cancer

Lung Cancer

Prostate Cancer

More Featured Trials
Search Featured Trials

Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Información en español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
You Can Quit Smoking Now!
Related Pages
Search for Clinical Trials
NCI's PDQ® registry of cancer clinical trials.

Thyroid Cancer Home Page
NCI's gateway for information about thyroid cancer.
Treating Hereditary Thyroid Cancer in Children

Untitled Document

Name of the Trial

Phase I/II Study of Vandetanib in Young Patients With Hereditary Medullary Thyroid Carcinoma (NCI-07-C-0189). See the protocol summary.

Principal Investigators

Dr. Frank Balis, NCI Center for Cancer Research, and Dr. Samuel Wells, Washington University, St. Louis.

Dr. Frank Balis
Dr. Frank Balis
Principal Investigator

Why This Trial Is Important

Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer, representing about 2-3 percent of thyroid cancer cases. Although MTC usually occurs in people who have no family history of the disease, about 25-40 percent of cases are hereditary. Hereditary MTC is associated with group of genetic disorders that are caused by inherited mutations in a gene called RET. People with these disorders usually develop MTC as children or young adults.

Surgery is the only curative therapy for patients with hereditary MTC. Patients whose tumors cannot be surgically removed (unresectable) or that recur following surgery need new treatment options.

In this trial, doctors are testing a new drug called vandetanib (Zactima) in young patients with advanced hereditary MTC. Vandetanib blocks the activity of the protein produced by the RET gene. Researchers believe that inhibiting the activity of the RET protein may cause tumors to shrink and reduce the levels of tumor biomarkers in patients with MTC. Besides looking for these treatment effects, doctors will assess the safety and the pharmacokinetics of vandetanib in these patients.

"MTC is the most common cause of death in patients with these genetic disorders, and the disease is relatively unresponsive to radiation therapy and standard or novel chemotherapeutic regimens," said Dr. Balis. "Vandetanib, unlike standard chemotherapy or radiation, specifically targets the genetic defect responsible for the development of these tumors."

Who Can Join This Trial

Researchers seek to enroll 21 patients aged 5 to 18 with hereditary MTC that cannot be removed surgically, has recurred, or has metastasized (spread). See the list of eligibility criteria.

Study Site and Contact Information

This study is taking place at the NIH Clinical Center in Bethesda, Md. For more information, call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The toll-free call is confidential.


Back to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health